BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting

BOSTON, June 5, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1 study of BPM 31510 (IV) in advanced solid tumors and BPM 31543 for the prevention of chemotherapy-induced alopecia at the American Society of…

BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer

BOSTON, April 27, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase II clinical trial for its drug candidate BPM 31510 in combination with gemcitabine for the potential treatment of pancreatic cancer. The primary objective of the trial is to evaluate…

BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting

BOSTON, April 18, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced five poster presentations showing new promising preclinical pancreatic cancer data, including new biomarkers for detection and improved treatment outcomes via the combination of BPM31510 with gemcitabine. Additionally new data demonstrates molecular drivers of endothelial cell…

BERG Appoints Michael A. Kiebish As Chief Precision Medicine Officer

New CPMO position spotlights growing importance of precision medicine in disease treatment Feb 23, 2016, 09:04 ET from BERG BOSTON, Feb. 23, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced the appointment of Michael A. Kiebish, Ph.D. as Chief Precision Medical Officer.  In the newly created role, Kiebish will…

BERG Appoints Narain To Chief Executive Officer; Haddock Joins As Chief Financial Officer/ Chief Operating Officer

BERG Hires Bristol-Myers Squibb Former Head of Finance Feb 09, 2016, 09:02 ET from BERG BOSTON, Feb. 9, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, has announced the appointment of Jason Haddock as Chief Financial Officer and Chief Operating Officer. Haddock brings to BERG over 20 years of experience in corporate…

Berg Joins U.K. Prime Minister’s Initiative, Genomics England to Sequence 100,000 Genomes

Boston based biotech company to apply its analytics platform to GENE Consortium data Sep 30, 2015, 10:23 ET from Berg BOSTON, Sept. 30, 2015 /PRNewswire/ — Berg, a Boston-based biopharmaceutical company at the forefront of precision medicine, today announced it will join an industry collaboration with Genomics England. Formed by U.K. Prime Minister David Cameron, Genomics England is partnering with innovative…

National Institutes of Health to Evaluate Berg’s Drug for the Treatment of Kidney Cancer

BOSTON, Sept. 8, 2015 — Berg, a Boston-based biopharmaceutical company, has announced that it has entered into a Materials-Cooperative Research and Development Agreement (M-CRADA) with the United States National Institutes of Health (NIH) for the treatment of kidney cancer. Dr. W. Marston Linehan, Chief of Urologic Oncology at the Center for Cancer Research at the National Cancer…

Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy

Jun 01, 2015, 08:00 ET from Berg BOSTON, June 1, 2015 /PRNewswire/ — Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American…

Berg and Medical University of South Carolina Announce First of Its Kind Collaboration to Discover Lupus Biomarker

Research Partnership Will Combine Efforts of Leading Lupus Experts With Berg’s Award Winning Technology to Develop New, Targeted Therapies May 12, 2014, 10:00 ET from Berg FRAMINGHAM, Mass. and CHARLESTON, S.C., May 12, 2014 /PRNewswire/ — Berg and the Medical University of South Carolina today announced a strategic partnership, designed to identify new therapeutic pathways and potential biomarkers to treat Lupus, the…

Berg And The Parkinson’s Institute And Clinical Center Announce Key Clinical Study Focused On Game-changing Innovations In Parkinson’s Disease Biomarker Discovery

Third Phase of Collaboration Aims to Unravel Mysteries of Disease by Identifying Disease Markers and Potential New Drug Targets Feb 18, 2014, 09:15 ET from Berg FRAMINGHAM, Mass. and SUNNYVALE, Calif., Feb. 18, 2014 /PRNewswire/ — Berg and the Parkinson’s Institute and Clinical Center today announced the next phase in their ongoing partnership, focused on identifying potential biomarkers that may lead…
1 2